MAZE · NASDAQ
Maze Therapeutics, Inc.
$33.05 +0.79 (+2.45%)
Company overview
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1 in Phase II clinical trials for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19 in Phase I clinical trials for the treatment of chronic kidney disease. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. Maze Therapeutics was incorporated in 2017 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.8B
- Employees
- 125
- Headquarters
- South San Francisco, CA
- Website
- mazetx.com
- CEO
- Jason V. Coloma
- Listed
- January 31, 2025
- P/E
- -12.04
- Dividend yield
- 0.00%
Company financials
- Revenue
- $20M
- Gross profit
- $18.4M
- Operating income
- -$134M
- EBITDA
- -$126M
- Net income
- -$123M
- EPS
- -$2.75
- Total assets
- $420M
- Total debt
- $61.2M
- Gross margin
- 92.04%
- Net margin
- -612.71%
- Earnings yield
- -8.30%
No product segmentation.
No annual segmentation.
MAZE
1D
NASDAQ
O30.80H32.48L30.14C32.26+1.89 (+6.22%)Vol401.85K
News